NEW YORK, Oct. 06, 2016 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTC:AXIM), a world leader in cannabinoid research and development, today announced that its Chief Executive Officer George E. Anastassov, MD, DDS, MBA, will speak at the first-ever symposium dedicated to providing the medical community of Mexico with information about the medical value of cannabidiol (CBD) derivatives in Mexico City on Oct. 8.
The First National Symposium on Medical Cannabis, which was created and is being hosted by Medical Marijuana, Inc.’s (MJNA) subsidiary HempMeds® Mexico, is part of Medical Marijuana, Inc.’s program to educate health professionals on the therapeutic uses of cannabis. In addition to Dr. Anastassov, the event will feature other renowned experts like like Dr. Saul Garza Morales, pediatric neurologist and researcher in Mexico, and Raul Elizalde, an inspiring activist dedicated to providing access to medical products derived from cannabis to the ones most in need.
Dr. Anastassov will speak to health professionals in attendance about the value of cannabinoids and hemp derivatives, including how AXIM Biotech is using cannabinoids (both synthetic and natural) in the Company’s extensive line of pharmaceutical and nutraceutical products.
“I’m looking forward to addressing members of the medical community about how our Company is using cannabinoids to find answers for health conditions with no known cure,” said Dr. Anastassov. “It will also be a perfect opportunity to network with other medical professionals and share international experience on the use of derivatives of cannabis in the treatment of a plethora of conditions and diseases. It is my hope that this dialogue will further cannabinoid sciences.”
AXIM® will start clinical trials for their combination CBD/THC controlled-release, trans-mucosal, functional chewing gum, MedChew® RX, for the treatment of pain and spasticity associated with multiple sclerosis. Directly compared to a sublingually delivered cannabis-based product currently on the market for MS, Reuters’ Global News Agency reported the potential for MedChew® Rx at an estimated $4.8 billion USD. MedChew® Rx is on track to be fully registered by the EMA and FDA.
Besides CanChew and MedChew Rx, AXIM is developing a pipeline of other innovative medications based on their proprietary trans-mucosal, controlled-release functional delivery systems. These contain different cannabinoids (both synthetic and natural) in variable doses for a variety of indications. Some contain other compounds besides cannabinoids for enhanced effectiveness of the preparations based on specific indications.
Another AXIM® Biotech patent-pending cannabis innovation in clinical trials is AX-1602. The first of its kind, AX-1602 contains CBG (cannabigerol) and other cannabinoids as a treatment for psoriasis and atopic dermatitis.
AXIM® Biotech’s core belief is responsibility for environmental stewardship combined with development of innovative products to address current conditions with no known effective treatment including: Parkinson’s disease, Alzheimer’s disease/dementia, ADHD (attention deficit hyperactivity disorder), PTSD, autism, MS, spasticity, pain, RLS (restless leg syndrome), glaucoma, IBD, IBS and Crohn’s disease, and treatment of nicotine and drug addictions as well as cannabis dependence.
About AXIM®
AXIM® Biotechnologies, Inc. (OTC:AXIM) is an innovative biotechnology Company focusing on research, development and production of pharmaceutical, nutraceutical and cosmetic products where we prioritize the well-being of our customers while embracing a solid fiscal strategy. For more information, visit the Company website at www.AXIMBiotech.com.
About HempMeds® Mexico
HempMeds® Mexico is a Mexico-based company that made history by being the first company to receive a COFEPRIS federal government import permit for the cannabis product RSHO-X™ for a medical indication. HempMeds® Mexico plans to work directly with the Mexican government to safely and legally provide access to CBD hemp oil products. For more information, please review the company’s website at: http://www.hempmeds.mx.
About Medical Marijuana, Inc.
Our mission is to be the premier cannabis and hemp industry innovators, leveraging our team of professionals to source, evaluate and purchase value-added companies and products, while allowing them to keep their integrity and entrepreneurial spirit. We strive to create awareness within our industry, develop environmentally-friendly, economically sustainable businesses, while increasing shareholder value. For details on Medical Marijuana, Inc.’s portfolio and investment companies, visit www.medicalmarijuanainc.com.
To see Medical Marijuana, Inc.’s video statement, click here. Shareholders are also encouraged to visit the Medical Marijuana, Inc. Shop for discounted products.
FORWARD-LOOKING DISCLAIMER
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Medical Marijuana, Inc. to be materially different from the statements made herein.
FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE
These statements have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease.
LEGAL DISCLOSURE
Medical Marijuana Inc. does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA). These companies do grow, sell, and distribute hemp-based products and are involved with the federally legal distribution of medical marijuana-based products within certain international markets. Cannabidiol is a natural constituent of hemp oil.
Public Relations Contact:
Andrew Hard
Chief Executive Officer
CMW Media
P. 888-829- 0070
andrew.hard@cmwmedia.com
www.cmwmedia.com
Corporate Business Contact:
Nicholas R. Massalas
Director of Business Development
Medical Marijuana, Inc.
OTC Symbol: MJNA
Toll Free: 888-OTC- MJNA (888-682- 6562)
www.medicalmarijuanainc.com
www.facebook.com/mjnainc
Investor Relations Contact:
EquiNet, LLC
Toll Free: (877) 964.6463
Office/Direct: (858) 264-6500
Email: info@equinet.us
www.equinet.us